Celgene is usually paying Evotec $45 million up front as part of a broad, five-year R& D collaboration that will leverage Evotec’ s caused pluripotent stem cell (iPSC) screening platform to identify disease-modifying drugs targeting a range of neurodegenerative diseases, including amyotrophic spectrum of ankle sclerosis, Alzheimer’ s disease, and Parkinson’ s illness.    

The deal gives Celgene exceptional options to license the worldwide rights to Evotec compounds identified from the latter’ s compound library. Evotec could receive up to $250 million in milestones, in addition double-digit sales royalties. Celgene also has the option to use the particular Evotec iPSC screening platform to evaluate compounds from its very own CELMoD® library, in models of neurodegenerative diseases.

“We are very pleased to enter into our first neurodegeneration cooperation with Evotec and look forward to the screening of their substance libraries using their proprietary iPSC platform, ” commented Rupert Vessey, evp and president of research and earlier development at Celgene. “ Recent breakthroughs in our knowledge of the mechanism of action of the CELMoD library might enable the discovery of other related compounds that may direct the degradation of proteins known to be neurotoxic. ”

Evotec’ s iPSC screening platform continues to be developed through a research collaboration and license agreement along with Harvard University, and in particular the CureMotorNeuron initiative, as well as with the firm’ s 10-year collaboration with the CHDI Foundation.

The deal with Celgene coincides with Evotec credit reporting completion of its £ 55. 7 million ($69. several million) acquisition of U. K. -based preclinical CRO Cyprotex. Earlier in December Evotec announced an alliance with Make Therapeutics focused on developing the latter’ s LpxC blockers against drug-resistant Gram-negative bacteria.